Skip to main navigation
Logo
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance and Compliance
    • Corporate Governance
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Overview
    • SEC Filings
    • Annuals and Proxies
  • Investor Contact

Press Releases

Jan 10, 2022
Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate
- Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 - Strong financial position supports investment in long-term growth drivers including pipeline expansion - Initiation of Phase 1 clinical trial of shingles vaccine
PDF Version
Jan 07, 2022
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , Jan. 7, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares
PDF Version
Jan 05, 2022
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
EMERYVILLE, Calif. , Jan. 5, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

Shareholder Tools

Footer Links - Column 1

  • About
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe

Footer Links - Column 2

  • Science
  • Overview
  • Publications & Presentations
  • CpG 1018

Footer Links - Column 3

  • Ongoing Studies
  • Overview
  • Ongoing Studies Listing
  • Partnership

Footer Links - Column 4

  • Investors
  • Overview
  • News & Events
  • Stock Information
  • Financials
  • Contact Us

Footer Links - Column 5

  • Product
  • HEPLISAV-B

Footer Links - Column 6

  • Portfolio

Footer Links - Column 7

  • Careers
  • Join Our Team
  • Job Opportunities
  • Benefits

GP - Contact IR Footer

  • Investor Contact

    Nicole Arndt
    Investor Relations
    narndt@dynavax.com

Legal Links

  • Terms & Conditions
  • Privacy Notice
  • © 2022 Dynavax Technologies Corporation. All rights reserved.